Literature DB >> 7670943

Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease.

P N Hopkins1, L L Wu, J Wu, S C Hunt, B C James, G M Vincent, R R Williams.   

Abstract

To examine the graded risks for coronary artery disease (CAD) associated with plasma homocyst(e)ine [H(e)] and to evaluate the extent to which this risk is mediated by altered vitamin status, we measured plasma concentrations of H(e), vitamins B6 and B12, and folate as well as other coronary risk factors in subjects with early familial CAD and in control subjects. We studied 120 male and 42 female patients with early CAD who were unrelated to each other but were from families in which at least one other sibling had early CAD. Control subjects were 85 men and 70 women with the same age range (38 to 68) as the subjects with CAD at screening. Increasing H(e) was associated with graded increased risks of CAD that appeared consistent with a multiplicative model. Relative odds for CAD were approximately 12.8 in women when those with H(e) levels of 9 mumol/L and above were compared with those with H(e) levels of 9 mumol/L or less (P = .007). For men, the same comparison yielded relative odds of 13.8 (P = .0002). Plasma H(e) remained a strong, independent risk factor after adjustment for standard risk factors and plasma vitamin levels in multiple logistic regression (relative odds, 8.1 for a 10-mumol/L increase in H(e); 95% confidence interval, 3.2 to 20.4; P < .0001). In multivariate ANCOVA the slope of H(e) versus folate was much steeper in subjects with CAD than in control subjects (P = .0035). These data suggest that high plasma H(e) is an important, independent contributor to risk for early familial CAD.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670943     DOI: 10.1161/01.atv.15.9.1314

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  The effect of a subnormal vitamin B-6 status on homocysteine metabolism.

Authors:  J B Ubbink; A van der Merwe; R Delport; R H Allen; S P Stabler; R Riezler; W J Vermaak
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 2.  The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia.

Authors:  J B Ubbink
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 3.  Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.

Authors:  B V Taylor; G Y Oudit; M Evans
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

4.  High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial.

Authors:  Howard N Hodis; Wendy J Mack; Laurie Dustin; Peter R Mahrer; Stanley P Azen; Robert Detrano; Jacob Selhub; Petar Alaupovic; Chao-ran Liu; Ci-hua Liu; Juliana Hwang; Alison G Wilcox; Robert H Selzer
Journal:  Stroke       Date:  2008-12-31       Impact factor: 7.914

Review 5.  Involvements of Hyperhomocysteinemia in Neurological Disorders.

Authors:  Marika Cordaro; Rosalba Siracusa; Roberta Fusco; Salvatore Cuzzocrea; Rosanna Di Paola; Daniela Impellizzeri
Journal:  Metabolites       Date:  2021-01-06

6.  Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis.

Authors:  Nícollas Nunes Rabelo; João Paulo Mota Telles; Leonardo Zumerkorn Pipek; Rafaela Farias Vidigal Nascimento; Rodrigo Coimbra de Gusmão; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.